| Breast Cancer |
1 |
1 |
| Ovarian Cancer |
0 |
0.85 |
| Biologic Therapy |
0 |
0.74 |
| Cancer |
0 |
0.72 |
| Endometrial Cancer |
0 |
0.68 |
| Cervical Cancer |
0 |
0.63 |
| Metastasis |
0 |
0.56 |
| Sentinel Lymph Node Biopsy |
0 |
0.53 |
| Cancer Staging |
0 |
0.52 |
| Targeted Cancer Therapy |
0 |
0.51 |
| COVID-19 |
0 |
0.48 |
| Sentinel Lymph Node |
0 |
0.42 |
| Lymph Node |
0 |
0.33 |
| Surgery |
0 |
0.28 |
| Biopsy |
0 |
0.26 |
| Platinum |
0 |
0.23 |
| Chemotherapy |
0 |
0.19 |
| Humanized Monoclonal Antibody |
0 |
0.15 |
| Angiogenesis Inhibitors |
0 |
0.14 |
| BRCA |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Histology |
0 |
0.07 |
| Resection |
0 |
0.07 |
| Pandemic |
0 |
0.05 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.05 |
| Remission |
0 |
0.05 |
| Anemia |
0 |
0.04 |
| Immunotherapy |
0 |
0.04 |
| Neutropenia |
0 |
0.04 |
| Tumor |
0 |
0.04 |
| Patient Safety |
0 |
0.03 |
| Postoperative Complications |
0 |
0.03 |
| Angiogenesis |
0 |
0.02 |
| Ascites |
0 |
0.02 |
| Biomarker |
0 |
0.02 |
| Body Mass Index |
0 |
0.02 |
| Cervix |
0 |
0.02 |
| Exercise |
0 |
0.02 |
| Hysterectomy |
0 |
0.02 |
| Injury |
0 |
0.02 |
| Lymphedema |
0 |
0.02 |
| Monoclonal Antibody |
0 |
0.02 |
| Ovary |
0 |
0.02 |
| Placebo Therapy |
0 |
0.02 |
| Postoperative |
0 |
0.02 |
| Prognosis |
0 |
0.02 |
| Residual Disease |
0 |
0.02 |
| Uterus |
0 |
0.02 |
| Wound Management |
0 |
0.02 |